Tandem Diabetes Care Valuation
Is T2ND34 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of T2ND34 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: T2ND34 (R$11.06) is trading below our estimate of fair value (R$20.59)
Significantly Below Fair Value: T2ND34 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for T2ND34?
Key metric: As T2ND34 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is T2ND34's PS Ratio? | |
|---|---|
| PS Ratio | 2.4x |
| Sales | US$854.35m |
| Market Cap | US$2.02b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.4x |
| Enterprise Value/EBITDA | -15.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does T2ND34's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.5x | ||
ODPV3 Odontoprev | 2.5x | 3.4% | R$5.9b |
FLRY3 Fleury | 1x | 6.5% | R$7.4b |
HAPV3 Hapvida Participações e Investimentos | 0.8x | 7.4% | R$22.3b |
NUVA NuVasive | 1.7x | 6.7% | US$2.1b |
T2ND34 Tandem Diabetes Care | 2.4x | 10.3% | R$2.0b |
Price-To-Sales vs Peers: T2ND34 is expensive based on its Price-To-Sales Ratio (2.4x) compared to the peer average (1.4x).
Price to Sales Ratio vs Industry
How does T2ND34's PS Ratio compare vs other companies in the Global Medical Equipment Industry?
| 135 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 135 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: T2ND34 is good value based on its Price-To-Sales Ratio (2.4x) compared to the Global Medical Equipment industry average (3.4x).
Price to Sales Ratio vs Fair Ratio
What is T2ND34's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.4x |
| Fair PS Ratio | 1.2x |
Price-To-Sales vs Fair Ratio: T2ND34 is expensive based on its Price-To-Sales Ratio (2.4x) compared to the estimated Fair Price-To-Sales Ratio (1.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Teladoc Health
US$1.8b
Provides virtual healthcare services worldwide.
T2DH34
US$2.06
7D
17.0%
1Y
-27.2%
Centene
US$30.5b
Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.
C1NC34
US$350.00
7D
3.8%
1Y
-4.5%
Koninklijke Philips
€23.6b
Operates as a health technology company in North America, the Greater China, and internationally.
PHGN34
€152.70
7D
2.0%
1Y
51.5%